Age-dependent differences in first-line chemotherapy in patients with metastatic colorectal cancer: the DISCO study

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7–30.
   PubMed Web of Science ®Google Scholar
• Christensen K, Doblhammer G, Rau R, et al. Ageing populations: the challenges ahead. Lancet. 2009;374:1196–1208.
   PubMed Web of Science ®Google Scholar
• Piessevaux H, Buyse M, Schlichting M. Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol. 2013;31:3764–3775.
   PubMed Web of Science ®Google Scholar
• Kopetz S, Chang GJ, Overman MJ, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. JCO. 2009;27:3677–3683.
   PubMed Web of Science ®Google Scholar
• Braendegaard Winther S, Baatrup G, Pfeiffer P, et al. Trends in colorectal cancer in the elderly in Denmark, 1980–2012. Acta Oncol. 2016;55(Suppl 1):29–39.
   PubMed Web of Science ®Google Scholar
• Hoeben KW, van Steenbergen LN, van de Wouw AJ, et al. Treatment and complications in elderly stage III colon cancer patients in the Netherlands. Ann Oncol. 2013;24:974–979.
   PubMed Web of Science ®Google Scholar
• Jackson NA, Barrueco J, Soufi-Mahjoubi R, et al. Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer: findings from the bolus, infusional, or capecitabine with camptostar-celecoxib study. Cancer. 2009;115:2617–2629.
   PubMed Web of Science ®Google Scholar
• Folprecht G, Seymour MT, Saltz L, et al. Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials. JCO. 2008;26:1443–1451.
   PubMed Web of Science ®Google Scholar
• Bosse D, Vickers M, Lemay F, et al. Palliative chemotherapy for patients 70 years of age and older with metastatic colorectal cancer: a single-centre experience. Curr Oncol. 2015;22:349–356.
   Web of Science ®Google Scholar
• Aparicio T, Lavau-Denes S, Phelip JM, et al. Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001-02). Ann Oncol. 2016;27:121–127.
   PubMed Web of Science ®Google Scholar
• Seymour MT, Thompson LC, Wasan HS, et al. Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial. Lancet. 2011;377:1749–1759.
   PubMed Web of Science ®Google Scholar
• Cunningham D, Lang I, Marcuello E, et al. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol. 2013;14:1077–1085.
   PubMed Web of Science ®Google Scholar
• Cassidy J, Saltz LB, Giantonio BJ, et al. Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies. J Cancer Res Clin Oncol. 2010;136:737–743.
   PubMed Web of Science ®Google Scholar
• Rouyer M, Fourrier-Reglat A, Smith D, et al. Effectiveness and safety of first-line bevacizumab plus FOLFIRI in elderly patients with metastatic colorectal cancer: results of the ETNA observational cohort. J Geriatr Oncol. 2016;7:187–194.
   PubMed Web of Science ®Google Scholar
• Jehn CF, Boning L, Kroning H, et al. Cetuximab-based therapy in elderly comorbid patients with metastatic colorectal cancer. Br J Cancer. 2012;106:274–278.
   PubMed Web of Science ®Google Scholar
• Hurria A, Togawa K, Mohile SG, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. Jco. 2011;29:3457–3465.
   PubMed Web of Science ®Google Scholar
• Gill S, Loprinzi CL, Sargent DJ, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol. 2004;22:1797–1806.
   PubMed Web of Science ®Google Scholar
• Kordatou Z, Kountourakis P, Papamichael D. Treatment of older patients with colorectal cancer: a perspective review. Ther Adv Med Oncol. 2014;6:128–140.
   PubMed Web of Science ®Google Scholar
• Power DG, Lichtman SM. Chemotherapy for the elderly patient with colorectal cancer. Cancer J. 2010;16:241–252.
   PubMed Web of Science ®Google Scholar
• Lund CM, Nielsen D, Dehlendorff C, et al. Efficacy and toxicity of adjuvant chemotherapy in elderly patients with colorectal cancer: the ACCORE study. ESMO Open. 2016;1:e000087.
   PubMed Web of Science ®Google Scholar
• Lieu CH, Renfro LA, de Gramont A, et al. Association of age with survival in patients with metastatic colorectal cancer: analysis from the ARCAD clinical trials program. J Clin Oncol. 2014: 32:2975–2984.
   PubMed Web of Science ®Google Scholar
• Papamichael D, Audisio RA, Glimelius B, et al. Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013. Ann Oncol. 2015;26:463–476.
   PubMed Web of Science ®Google Scholar
• Vincent MD, Breader D, Cripps MC, et al. Phase I/II trial of dose-reduced capecitabine in elderly patients with advanced colorectal cancer. Curr Oncol. 2017;24:261–e268.
   Web of Science ®Google Scholar
• O'Connell JB, Maggard MA, Livingston EH, et al. Colorectal cancer in the young. Am J Surg. 2004;187:343–348.
   PubMed Web of Science ®Google Scholar
• Hotta K, Ueoka H, Kiura K, et al. An overview of 48 elderly-specific clinical trials of systemic chemotherapy for advanced non-small cell lung cancer. Lung Cancer. 2004;46:61–76.
   PubMed Web of Science ®Google Scholar
• Razenberg LG, van Erning FN, Pruijt HF, et al. The impact of age on first-line systemic therapy in patients with metachronous metastases from colorectal cancer. J Geriatr Oncol. 2017;8:37–43.
   PubMed Web of Science ®Google Scholar
• Goldberg RM, Tabah-Fisch I, Bleiberg H, et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. JCO. 2006;24:4085–4091.
   PubMed Web of Science ®Google Scholar
• Extermann M, Aapro M, Bernabei R, et al. Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol. 2005;55:241–252.
   PubMed Web of Science ®Google Scholar
• Doat S, Thiebaut A, Samson S, et al. Elderly patients with colorectal cancer: treatment modalities and survival in France. National data from the ThInDiT cohort study. Eur J Cancer. 2014;50:1276–1283.
   PubMed Web of Science ®Google Scholar
• Lund CM, Vistisen KK, Dehlendorff C, et al. The effect of geriatric intervention in frail elderly patients receiving chemotherapy for colorectal cancer: a randomized trial (GERICO). BMC Cancer. 2017;17:448.
   PubMed Web of Science ®Google Scholar
• Gervaz P, Usel M, Rapiti E, et al. Right colon cancer: left behind. Eur J Surg Oncol. 2016;42:1343–1349.
   PubMed Web of Science ®Google Scholar
• Tournigand C, Andre T, Bonnetain F, et al. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial. JCO. 2012;30:3353–3360.
   PubMed Web of Science ®Google Scholar
• Aparicio T, Pamoukdjian F, Quero L, et al. Colorectal cancer care in elderly patients: unsolved issues. Dig Liver Dis. 2016;48:1112–1118.
   PubMedGoogle Scholar
• Winther SB, Osterlund P, Berglund A, et al. Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9. BMC Cancer. 2017;17:548.
   PubMed Web of Science ®Google Scholar
• McCleary NJ, Hubbard J, Mahoney MR, et al. Challenges of conducting a prospective clinical trial for older patients: lessons learned from NCCTG N0949 (alliance). J Geriatr Oncol. 2018;9:24–31.
   PubMed Web of Science ®Google Scholar
• Kelly CM, Power DG, Lichtman SM. Targeted therapy in older patients with solid tumors. J Clin Oncol. 2014;32:2635–2646.
   PubMed Web of Science ®Google Scholar